Morgan Stanley Kaleido Biosciences, Inc. Transaction History

Morgan Stanley

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.05 - $1.7 $477 - $16,241	-9,554 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$1.3 - $2.7 $12,420 - $25,795	9,554 New	9,554 $14,000
Q1 2022 May 13, 2022	SELL	$1.3 - $2.7 $11,700 - $24,300	-9,000 Reduced 48.51%	9,554 $14,000
Q4 2021 Feb 14, 2022	SELL	$2.39 - $6.02 $35,835 - $90,263	-14,994 Reduced 44.69%	18,554 $43,000
Q3 2021 Nov 15, 2021	BUY	$5.36 - $7.99 $179,817 - $268,048	33,548 New	33,548 $184,000

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.